Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Vopr Onkol ; 61(1): 40-4, 2015.
Artigo em Russo | MEDLINE | ID: mdl-26016144

RESUMO

Application of modern linear electron accelerators, equipped with precise navigation systems, maximum conformal dose delivery as well as imaging of irradiated focus significantly increased possibilities of escalating of doses of ionizing radiation in a selected volume with the necessary protection of the surrounding critical structures. These technological solutions and modern ideas about possibilities of remote beam radiation therapy resulted in a significant increase of the role of radiation therapy and, in particular, stereotactic radiotherapy in the treatment of patients with liver metastases. This technique allows creating locally in metastatic tumor site a high dose of ionizing radiation causing by that the destruction of the tumor. This promising direction in treatment of liver metastases significantly expanded possibilities of complex treatment and enabled us to provide specific assistance to those patients who have been rejected from other methods of treatment.


Assuntos
Neoplasias Hepáticas/secundário , Neoplasias Hepáticas/cirurgia , Radiocirurgia , Radioterapia Conformacional/métodos , Adulto , Idoso , Feminino , Humanos , Neoplasias Hepáticas/radioterapia , Masculino , Pessoa de Meia-Idade , Dosagem Radioterapêutica , Técnicas Estereotáxicas , Resultado do Tratamento
2.
Vopr Onkol ; 61(1): 121-4, 2015.
Artigo em Russo | MEDLINE | ID: mdl-26016157

RESUMO

Morbidity and mortality from pancreatic cancer is steadily increasing. Resectable cases are not more than 20%. Conventional schemes of chemoradiation and radiation therapy are durable over the time, have toxicity and low treatment outcomes. Many foreign authors consider as promising the technique of stereotactic radiotherapy, which is often used in pancreatic cancer and permit achieving high local control. At our institution there has been developed and introduced into clinical practice a method of stereotactic radiotherapy for the palliative treatment of patients with pancreatic cancer, which improved not only the duration but also the quality of life of patients.


Assuntos
Cuidados Paliativos/métodos , Neoplasias Pancreáticas/cirurgia , Qualidade de Vida , Radiocirurgia , Feminino , Humanos , Pessoa de Meia-Idade , Neoplasias Pancreáticas/diagnóstico por imagem , Análise de Sobrevida , Tomografia Computadorizada por Raios X , Resultado do Tratamento
3.
Vopr Onkol ; 61(1): 141-4, 2015.
Artigo em Russo | MEDLINE | ID: mdl-26016161

RESUMO

Since February 2012, in order to increase the effectiveness of treatment and quality of life of patients with disseminated disease, there was developed and implemented a method of stereotactic radiotherapy for metastatic lesion of lungs by tumors of different histological types. 20 patients were treated by stereotactic radiotherapy ROD 7 Gy in five sessions during 5 days. There were evaluated results of treatment and prospects of this method.


Assuntos
Neoplasias Pulmonares/radioterapia , Neoplasias Pulmonares/secundário , Qualidade de Vida , Técnicas Estereotáxicas , Adulto , Idoso , Feminino , Humanos , Neoplasias Pulmonares/diagnóstico por imagem , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Radioterapia/métodos , Dosagem Radioterapêutica , Tomografia Computadorizada por Raios X , Resultado do Tratamento
4.
Vopr Onkol ; 61(6): 965-7, 2015.
Artigo em Russo | MEDLINE | ID: mdl-26995988

RESUMO

Brain metastases in breast cancer develop for 24-32 months after the detection of the primary tumor. The study included patients with brain metastases who were divided into three groups: the first group--with early chemoradiotherapy (CRT) without induction chemotherapy (IC) by capecitabine; the second group--with delayed CRT with 4 or 8 courses of IC by capecitabine; the third group (a historical control) who received only whole brain radiation therapy. The median time to progression of intracranial metastases was 15.3, 12 and 5 months, respectively. The median time to the intracranial progression significantly less in the third group (5 months) compared with the first (15.3 months) (p = 0.0007) and the second (12 months) (p = 0.027) groups. The overall survival rate was 22.1, 15.1 and 6.8 months in three groups, respectively.


Assuntos
Antineoplásicos/administração & dosagem , Neoplasias Encefálicas/terapia , Neoplasias da Mama/terapia , Capecitabina/administração & dosagem , Quimiorradioterapia Adjuvante , Irradiação Craniana , Adulto , Idoso , Neoplasias Encefálicas/mortalidade , Neoplasias Encefálicas/secundário , Neoplasias da Mama/mortalidade , Neoplasias da Mama/patologia , Terapia Combinada , Intervalo Livre de Doença , Feminino , Humanos , Pessoa de Meia-Idade , Federação Russa/epidemiologia , Análise de Sobrevida , Fatores de Tempo , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...